Floatz logo

Ipilimumab

Anal Canal Undifferentiated Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Anal Canal Undifferentiated Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
ECOG-ACRIN Cancer Research Group
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
M.D. Anderson Cancer Center
Phase 2B
Toripalimab
Sun Yat-sen University
Phase 2B
FLUOROURACILUM
ECOG-ACRIN Cancer Research Group
Phase 2B
Durvalumab
M.D. Anderson Cancer Center
Phase 2CCC

View all 14 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →